Sanofi, Regeneron reports cSCC data for PD-1 inhibitor cemiplimab

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported top-line data from 82 evaluable patients with advanced cutaneous squamous cell carcinoma (cSCC) in the pivotal Phase II EMPOWER-CSCC 1 trial showing that cemiplimab (REGN2810, SAR439684) led to an overall response rate (ORR) of 46.3%. Median duration of response has not been reached in the open-label, international, single-arm trial.

EMPOWER-CSCC 1 is evaluating 3 mg/kg cemiplimab every two weeks and 350 mg cemiplimab every three weeks in patients with metastatic cSCC and 3 mg/kg cemiplimab every two weeks to treat locally advanced and unresectable cSCC...